Biogen inks $380M Alzheimer's deal with Neurimmune

Biogen Idec has struck a deal with Switzerland's Neurimmune Therapeutics to develop antibodies that attack the amyloid beta plaque fingered as a prime culprit in the neurodegenerative symptoms of Alzheimer's. Neurimmune will employ its technology platform to identify antibodies that bind to the plaque in exchange for up to $380 million in total fees and milestones. There are no therapies approved to slow or stop the disease.

- see Biogen's release
- here's the AFX report for more info

Related Articles:
Big pharma sees big payback for Alzheimer's research. Report
Biogen stock sinks as investors do reality check. Report
Sources: Biogen gets bidders, with Pfizer in lead. Report
What's Biogen Idec really worth to Big Pharma? Report
Biogen Idec in play after Icahn makes his move. Report